Despite great hopes, checkpoint inhibitors targeting either PD-1, PD-L1 or cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) applied as monotherapies have not yielded clinical improvements for PDAC patients in contrast to therapeutic successes in other cancers [39,40,41,42]. Here, PDCD1 is linked to cancer.